-
Something wrong with this record ?
A fixed combination of cinnarizine/dimenhydrinate for the treatment of patients with acute vertigo due to vestibular disorders : a randomized, reference-controlled clinical study
A Hahn, I Sejna, B Stefflova, M Schwarz, W Baumann
Language English Country New Zealand
Document type Comparative Study
NLK
ProQuest Central
from 2008-06-01 to 1 year ago
Health & Medicine (ProQuest)
from 2008-06-01 to 1 year ago
- MeSH
- Acute Disease MeSH
- Time Factors MeSH
- Cinnarizine chemistry therapeutic use MeSH
- Dimenhydrinate chemistry therapeutic use MeSH
- Adult MeSH
- Double-Blind Method MeSH
- Financing, Organized MeSH
- Drug Combinations MeSH
- Middle Aged MeSH
- Humans MeSH
- Periodicity MeSH
- Randomized Controlled Trials as Topic MeSH
- Aged MeSH
- Tablets MeSH
- Vertigo etiology drug therapy MeSH
- Vestibular Diseases complications MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Comparative Study MeSH
BACKGROUND AND OBJECTIVE: Vestibular dysfunction commonly leads to - often severe - vertigo symptoms. The objective of this study was to compare the antivertiginous efficacy and tolerability of a fixed combination of cinnarizine/dimenhydrinate with those of betahistine in patients with acute vertigo due to vestibular disorders. METHODS: Sixty-six patients experiencing acute vertigo attacks participated in this prospective, double-blind, three-centre, comparative study. Patients who assessed at least one vertigo symptom as being of medium intensity (> or =2) on a 5-point visual analogue scale (VAS; from 0 = no symptoms to 4 = very severe symptoms) were randomly allocated to treatment with the fixed combination of cinnarizine 20 mg and dimenhydrinate 40 mg three times daily or betahistine 12 mg three times daily for 4 weeks. The primary efficacy endpoint was change in mean vertigo score, as determined by patients' assessments of 12 individual vertigo symptoms on the 5-point VAS after 4 weeks of treatment. RESULTS: Treatment with the fixed combination led to significantly greater improvements in mean vertigo scores than the reference therapy betahistine after 4 weeks of therapy (p = 0.013). The differences were clinically relevant, based on the Mann-Whitney estimator. Furthermore, the incidence of vertigo-associated vegetative symptoms was significantly reduced after 1 (p = 0.004) and 4 weeks (p = 0.023) in the fixed-combination group relative to the betahistine group. Three patients, all of them in the betahistine group, reported adverse events, none of which was considered serious. Almost all patients (n = 62) rated the tolerabilities of both medications as very good or good. CONCLUSION: The fixed combination of cinnarizine/dimenhydrinate was shown to be an effective and very well tolerated treatment option for patients with acute vertigo due to vestibular disorders. The combination proved to be significantly more efficient in reducing vertigo and associated vegetative symptoms than betahistine in such patients.
- 000
- 03867naa 2200493 a 4500
- 001
- bmc10034989
- 003
- CZ-PrNML
- 005
- 20111210200447.0
- 008
- 101221s2008 nz e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a nz
- 100 1_
- $a Hahn, Aleš, $d 1947-2020 $7 nlk19990073180
- 245 12
- $a A fixed combination of cinnarizine/dimenhydrinate for the treatment of patients with acute vertigo due to vestibular disorders : a randomized, reference-controlled clinical study / $c A Hahn, I Sejna, B Stefflova, M Schwarz, W Baumann
- 314 __
- $a Ear, Nose and Throat Department, Faculty Hospital Kralovske Vinohrady (FNKV), 3rd Medical Faculty, Charles University, Prague, Czech Republic.
- 520 9_
- $a BACKGROUND AND OBJECTIVE: Vestibular dysfunction commonly leads to - often severe - vertigo symptoms. The objective of this study was to compare the antivertiginous efficacy and tolerability of a fixed combination of cinnarizine/dimenhydrinate with those of betahistine in patients with acute vertigo due to vestibular disorders. METHODS: Sixty-six patients experiencing acute vertigo attacks participated in this prospective, double-blind, three-centre, comparative study. Patients who assessed at least one vertigo symptom as being of medium intensity (> or =2) on a 5-point visual analogue scale (VAS; from 0 = no symptoms to 4 = very severe symptoms) were randomly allocated to treatment with the fixed combination of cinnarizine 20 mg and dimenhydrinate 40 mg three times daily or betahistine 12 mg three times daily for 4 weeks. The primary efficacy endpoint was change in mean vertigo score, as determined by patients' assessments of 12 individual vertigo symptoms on the 5-point VAS after 4 weeks of treatment. RESULTS: Treatment with the fixed combination led to significantly greater improvements in mean vertigo scores than the reference therapy betahistine after 4 weeks of therapy (p = 0.013). The differences were clinically relevant, based on the Mann-Whitney estimator. Furthermore, the incidence of vertigo-associated vegetative symptoms was significantly reduced after 1 (p = 0.004) and 4 weeks (p = 0.023) in the fixed-combination group relative to the betahistine group. Three patients, all of them in the betahistine group, reported adverse events, none of which was considered serious. Almost all patients (n = 62) rated the tolerabilities of both medications as very good or good. CONCLUSION: The fixed combination of cinnarizine/dimenhydrinate was shown to be an effective and very well tolerated treatment option for patients with acute vertigo due to vestibular disorders. The combination proved to be significantly more efficient in reducing vertigo and associated vegetative symptoms than betahistine in such patients.
- 650 _2
- $a akutní nemoc $7 D000208
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a cinarizin $x chemie $x terapeutické užití $7 D002936
- 650 _2
- $a dimenhydrinát $x chemie $x terapeutické užití $7 D004111
- 650 _2
- $a dvojitá slepá metoda $7 D004311
- 650 _2
- $a fixní kombinace léků $7 D004338
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a periodicita $7 D010507
- 650 _2
- $a tablety $7 D013607
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a vertigo $x etiologie $x farmakoterapie $7 D014717
- 650 _2
- $a vestibulární nemoci $x komplikace $7 D015837
- 650 _2
- $a financování organizované $7 D005381
- 650 _2
- $a randomizované kontrolované studie jako téma $7 D016032
- 655 _2
- $a srovnávací studie $7 D003160
- 700 1_
- $a Šejna, Ivan. $7 xx0216530
- 700 1_
- $a Štefflová, Bohdana. $7 xx0246331
- 700 1_
- $a Schwarz, M
- 700 1_
- $a Baumann, W
- 773 0_
- $w MED00001123 $t Clinical drug investigation $g Roč. 28, č. 2 (2008), s. 89-99 $x 1173-2563
- 910 __
- $a ABA008 $b x $y 7
- 990 __
- $a 20110223133337 $b ABA008
- 991 __
- $a 20110414155526 $b ABA008
- 999 __
- $a ok $b bmc $g 823426 $s 688853
- BAS __
- $a 3
- BMC __
- $a 2008 $b 28 $c 2 $d 89-99 $i 1173-2563 $m Clinical drug investigation $n Clin. drug invest. $x MED00001123
- LZP __
- $a 2011-2B/ewme